DK1537114T3 - Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande - Google Patents

Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande

Info

Publication number
DK1537114T3
DK1537114T3 DK03784194T DK03784194T DK1537114T3 DK 1537114 T3 DK1537114 T3 DK 1537114T3 DK 03784194 T DK03784194 T DK 03784194T DK 03784194 T DK03784194 T DK 03784194T DK 1537114 T3 DK1537114 T3 DK 1537114T3
Authority
DK
Denmark
Prior art keywords
treatment
compounds
formula
aldosterone
agents
Prior art date
Application number
DK03784194T
Other languages
Danish (da)
English (en)
Inventor
Kenna Jeffrey Mc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1537114T3 publication Critical patent/DK1537114T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK03784194T 2002-08-07 2003-08-06 Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande DK1537114T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40169302P 2002-08-07 2002-08-07

Publications (1)

Publication Number Publication Date
DK1537114T3 true DK1537114T3 (da) 2006-11-13

Family

ID=31715720

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03784194T DK1537114T3 (da) 2002-08-07 2003-08-06 Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande

Country Status (15)

Country Link
US (1) US7732603B2 (de)
EP (1) EP1537114B8 (de)
JP (1) JP4533139B2 (de)
CN (1) CN100404535C (de)
AT (1) ATE335744T1 (de)
AU (1) AU2003253387A1 (de)
BR (1) BR0313293A (de)
CA (1) CA2494636A1 (de)
CY (1) CY1106217T1 (de)
DE (1) DE60307483T2 (de)
DK (1) DK1537114T3 (de)
ES (1) ES2270143T3 (de)
HK (1) HK1080290A1 (de)
PT (1) PT1537114E (de)
WO (1) WO2004014914A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568165A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
AR049711A1 (es) * 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP1842543A1 (de) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmazeutishe Zusammensetzung enthaltend einen Aldosteron-Synthase-Inhibitor und einen Mineralkorticoidrezeptor-Antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
US20100240641A1 (en) * 2006-05-26 2010-09-23 Julien Papillon Aldosterone Synthase and/or 11B-hydroxylase Inhibitors
WO2008027284A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EP2125823B1 (de) * 2006-12-22 2012-02-15 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazinderivate
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
CN101686989B (zh) 2007-06-21 2016-10-19 卡拉治疗学股份有限公司 取代的咪唑并杂环
CA2726834A1 (en) * 2008-06-25 2009-12-30 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112012025101B1 (pt) 2010-04-02 2021-08-31 Ogeda S.A. Compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e medicamento compreendendo os mesmos
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
AU2012282109B2 (en) 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
RS54833B1 (sr) 2011-10-03 2016-10-31 Euroscreen Sa Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
PL3197876T3 (pl) 2014-09-25 2019-05-31 Ogeda Sa NOWATORSKA SYNTEZA ASYMETRYCZNA N-ACYLO-(3-PODSTAWIENIE)- (8-PODSTAWIENIE)-5,6-DIHYDRO-[1,2,4] TRIAZOLO[4,3-a]PIRAZYN
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
RU2020131507A (ru) 2018-03-29 2022-05-04 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
US10899769B2 (en) 2018-04-06 2021-01-26 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
EP3887388A1 (de) 2018-11-27 2021-10-06 Novartis AG Zyklische peptide als proprotein-konvertase-subtilisin-/kexin typ 9 (pcsk9) zur behandlung von stoffwechselstörungen
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582315A (en) * 1968-03-22 1971-06-01 Lilly Co Eli Methods and compositions for inhibiting plant growth
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JPH07101959A (ja) * 1993-09-30 1995-04-18 Sankyo Co Ltd １−メチルカルバペネム誘導体
DE4341453A1 (de) * 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
EP1537114B8 (de) 2007-10-03
US20060166973A1 (en) 2006-07-27
HK1080290A1 (en) 2006-04-21
CN100404535C (zh) 2008-07-23
ATE335744T1 (de) 2006-09-15
EP1537114A1 (de) 2005-06-08
CN1688583A (zh) 2005-10-26
DE60307483D1 (de) 2006-09-21
CY1106217T1 (el) 2011-06-08
PT1537114E (pt) 2006-12-29
DE60307483T2 (de) 2007-07-05
US7732603B2 (en) 2010-06-08
WO2004014914A1 (en) 2004-02-19
ES2270143T3 (es) 2007-04-01
CA2494636A1 (en) 2004-02-19
AU2003253387A1 (en) 2004-02-25
EP1537114B1 (de) 2006-08-09
BR0313293A (pt) 2005-06-14
JP2006505520A (ja) 2006-02-16
JP4533139B2 (ja) 2010-09-01

Similar Documents

Publication Publication Date Title
DK1537114T3 (da) Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
DE60321593D1 (de) Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
WO2008076336A3 (en) Imidazoles as aldosterone synthase inhibitors
WO2007117982A3 (en) Organic compounds
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
UA96737C2 (ru) Конденсированные производные имидазола для ингибирования альдостеронсинтазы и ароматазы
IL231576A0 (en) Adamantyl acetamide derivatives as 11-beta-hydroxysteroid dehydrogenase type 1 enzyme inhibitors
UA84453C2 (ru) Применение производных метиленамида для лечения сердечно-сосудистых заболеваний
AR057882A1 (es) Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
WO2009079412A3 (en) Reverse transcriptase inhibitors
DK2049491T3 (da) Heteroaryl-sammensætninger anvendelige som inhibitorer af enzymer, der aktiverer E1
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
NO20060247L (no) Substituerte spirobenzazepiner
GEP20094604B (en) NEW ASSOCIATION OF A SINUS NODE if CURRENT INHIBITOR AND AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
NO20080392L (no) Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1
WO2005121102A3 (en) Factor viia inhibitor
WO2005118554A3 (en) Factor viia inhibitor
WO2007124355A3 (en) Vascular endothelial receptor specific inhibitors
WO2006018019A3 (de) SELEKTIVE INHIBITOREN DER 11ß-HYDROXYSTEROID-DEHYDROGENASE TYP 1
ITVA20040015A1 (it) Inibitore di corrosione concentrato per miscele refrigeranti, metodo di produzione di miscele refrigeranti ed inibizione di miscele refrigeranti esaurite.
ATE526972T1 (de) Kaliumkanalhemmer